Alisol B ameliorated metabolic dysfunction-associated steatotic liver disease via regulating purine metabolism and restoring the gut microbiota disorders
Our results demonstrate that AB treatment attenuates HFD-induced MASLD through dual mechanisms involving gut microbiota modulation and restoration of hepatic metabolic homeostasis. Comprehensive mechanistic analysis revealed that AB ameliorates hepatic steatosis and corrects purine metabolism dysregulation in MASLD pathogenesis through specific inhibition of XO. These findings provide novel mechanistic insights into the hepatoprotective properties of AB and establish its therapeutic potential for MASLD intervention.
Authors
- Xiaobing Dou (ORCID: https://orcid.org/0000-0002-2465-3079)
- Lin Chen (ORCID: https://orcid.org/0000-0003-3399-8711)
- Congcong Zhang (ORCID: https://orcid.org/0000-0001-9995-3079)
- Qingsheng Liu (ORCID: https://orcid.org/0000-0003-2721-4618)
- Yilong Fu (ORCID: https://orcid.org/0000-0002-2880-177X)
- Fucai Liu (ORCID: https://orcid.org/0000-0002-2769-8854)
- Yu Zhi-Ling
- Qiu Jiannan
- Ren Guilin
Institutions
- Zhejiang Chinese Medical University (CN)
- Hong Kong Baptist University (HK)
- Chinese University of Hong Kong (HK)
- Third People's Hospital of Hangzhou (CN)
Publication Details
- Journal
- Phytomedicine
- Published
- 2025-06-22
- DOI
- https://doi.org/10.1016/j.phymed.2025.156992
- Citations
- 2
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.71